Balyasny Asset Management L.P. Has $3.33 Million Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Balyasny Asset Management L.P. trimmed its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 70.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,202 shares of the medical equipment provider's stock after selling 89,933 shares during the quarter. Balyasny Asset Management L.P. owned approximately 0.05% of Lantheus worth $3,328,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB bought a new stake in Lantheus during the 3rd quarter worth approximately $25,000. Kestra Investment Management LLC bought a new stake in Lantheus during the 4th quarter worth approximately $27,000. Summit Securities Group LLC bought a new stake in Lantheus during the 4th quarter worth approximately $37,000. UMB Bank n.a. grew its holdings in Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after acquiring an additional 134 shares during the last quarter. Finally, Parkside Financial Bank & Trust boosted its stake in shares of Lantheus by 49.4% in the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock valued at $76,000 after purchasing an additional 280 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Trading Up 1.8%

NASDAQ LNTH traded up $1.46 on Friday, hitting $81.24. 913,883 shares of the company were exchanged, compared to its average volume of 981,515. The company has a market cap of $5.62 billion, a PE ratio of 13.52 and a beta of 0.23. Lantheus Holdings, Inc. has a 12 month low of $75.00 and a 12 month high of $126.89. The stock has a fifty day moving average of $97.11 and a 200-day moving average of $93.20.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by ($0.11). The company had revenue of $372.76 million for the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm's revenue was up .8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.69 earnings per share. On average, analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares of the company's stock, valued at $41,551,645.65. This represents a 10.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares in the company, valued at approximately $11,445,207.20. This represents a 8.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 63,109 shares of company stock valued at $6,016,046 over the last ninety days. 1.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on LNTH shares. Truist Financial reduced their price objective on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. StockNews.com raised shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Finally, B. Riley reduced their price objective on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $132.67.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.